Switzerland’s Roche has discontinued RG6540, an experimental off-the-shelf CAR-T therapy targeting the CD19 and CD20 proteins, less than two years after agreeing to acquire its developer, Poseida Therapeutics, for up to $1.5 billion (€1.3 billion). Roche has not explained the reasons for the decision, but CEO Thomas Schinecker told reporters that the acquisition had yielded other CD19/CD20 candidates he considers superior.
Roche, Herzog&De Meuron